Insiders / RA Capital Management, L.P.
RA Capital Management, L.P.
CIK 1346824personinsiderbeneficial ownerfund
Companies
25
First seen
Jan 7, 2026
Last activity
Aug 7, 2026
Companies
| Company | Shares held | Latest |
|---|---|---|
| Artiva Biotherapeutics, Inc. · ARTV | 16,795,919 | — |
| Prelude Therapeutics Incorporated · PRLD | 6,475,882 | — |
| Hemab Therapeutics Holdings, Inc. · COAG | 6,444,637 | — |
| Mineralys Therapeutics Inc · MLYS | 5,825,521 | — |
| Bicara Therapeutics Inc. · BCAX | 4,603,418 | — |
| Climb Bio, Inc. · CLYM | 3,403,429 | — |
| Evommune, Inc. · EVMN | 2,710,293 | — |
| Parabilis Medicines, Inc. · PBLS | 2,648,278 | — |
| Vor Biopharma Inc. · VOR | 2,402,095 | — |
| SpyGlass Pharma, Inc. · SGP | 2,054,678 | — |
All securities held
37 positions · latest reported per filing
| Company | Security | Shares |
|---|---|---|
| Acrivon Therapeutics, Inc. | Common Stock | 9,366 |
| Acrivon Therapeutics, Inc. | Stock Option (Right to Buy)Derivative | 20,275 |
| Acumen Pharmaceuticals, Inc. | Common Stock | 48,300 |
| Acumen Pharmaceuticals, Inc. | Stock Option (Right to Buy)Derivative | 53,250 |
| Adicet Bio, Inc. | Common Stock | 932,624 |
| Adicet Bio, Inc. | Pre-Funded Warrant (Right to Buy)Derivative | 1,402,833 |
| ARS Pharmaceuticals, Inc. | Stock Option (Right to Buy)Derivative | 30,000 |
| Artiva Biotherapeutics, Inc. | Common Stock | 16,795,919 |
| Artiva Biotherapeutics, Inc. | Pre-Funded Warrant (Right to Buy)Derivative | 2,170,138 |
| Bicara Therapeutics Inc. | Common Stock | 4,603,418 |
| Bicara Therapeutics Inc. | Pre-Funded Warrant (Right to Buy)Derivative | 2,200,000 |
| Bicara Therapeutics Inc. | Stock Option (Right to Buy)Derivative | 19,475 |
| Climb Bio, Inc. | Common Stock | 3,403,429 |
| Climb Bio, Inc. | Pre-Funded Warrants (Right to Buy)Derivative | 22,546,000 |
| Climb Bio, Inc. | Stock Option (Right to Buy)Derivative | 40,000 |
| Evommune, Inc. | Common Stock | 2,710,293 |
| Hemab Therapeutics Holdings, Inc. | Common Stock | 6,444,637 |
| Janux Therapeutics, Inc. | Common Stock | 11,750 |
| Janux Therapeutics, Inc. | Stock Option (Right to Buy)Derivative | 15,500 |
| LENZ Therapeutics, Inc. | Stock Option (right to buy)Derivative | 22,100 |
| Mineralys Therapeutics Inc | Common Stock | 5,825,521 |
| Mineralys Therapeutics Inc | Stock Option (Right to Buy)Derivative | 8,300 |
| Nkarta, Inc. | Stock Option (right to buy)Derivative | 37,000 |
| Parabilis Medicines, Inc. | Voting Common Stock | 2,648,278 |
| Parabilis Medicines, Inc. | Stock Option (Right to Buy)Derivative | 20,215 |
| PepGen Inc. | Stock Option (Right to Buy)Derivative | 34,000 |
| Prelude Therapeutics Incorporated | Common Stock | 6,475,882 |
| Prelude Therapeutics Incorporated | Pre-Funded Warrants (Right to Buy)Derivative | 1,407,000 |
| Septerna, Inc. | Stock Option (Right to Buy)Derivative | 15,000 |
| Sionna Therapeutics, Inc. | Non-Qualified Stock Option (right to buy)Derivative | 17,340 |
| SpyGlass Pharma, Inc. | Common Stock | 2,054,678 |
| SpyGlass Pharma, Inc. | Stock Option (right to buy)Derivative | 27,400 |
| Tyra Biosciences, Inc. | Stock Option (Right to Buy)Derivative | 13,160 |
| Vor Biopharma Inc. | Common Stock | 2,402,095 |
| Vor Biopharma Inc. | Stock Option (Right to Buy)Derivative | 57,162 |
| Wave Life Sciences Ltd. | Ordinary Shares | 26,975,505 |
| Werewolf Therapeutics, Inc. | Common Stock | 303,719 |
Activity
InsidersInstitutions
This person's insider trades (Form 4), across every company.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Jan 7, 2026 | Other | CDTX Cidara Therapeutics, Inc. Common Stock | $1.03B | -4.7M -100.00% | 0 0.00% of shares | low |
| Jun 11, 2026 | Buy | PBLS Parabilis Medicines, Inc. Voting Common Stock | $394.57M | +19.7M +300.89% | 26,285,093 21.56% of shares | high |
| May 11, 2026 | Buy | ARTV Artiva Biotherapeutics, Inc. Common Stock | $75.00M | +6.5M +74.89% | 15,203,995 31.10% of shares | high |
| Feb 9, 2026 | Buy | SGP SpyGlass Pharma, Inc. Common Stock | $55.07M | +3.4M +136.34% | 5,966,439 17.84% of shares | high |
| May 4, 2026 | Buy | COAG Hemab Therapeutics Holdings, Inc. Common Stock | $45.74M | +2.5M +70.44% | 6,149,096 13.16% of shares | high |
| Mar 26, 2026 | Buy | WVE Wave Life Sciences Ltd. Ordinary Shares | $30.02M | +5.0M +27.22% | 23,157,567 11.75% of shares | high |
| Jun 11, 2026 | Buy | PBLS Parabilis Medicines, Inc. Voting Common Stock | $29.21M | +1.5M +122.94% | 2,648,278 2.17% of shares | high |
| Mar 16, 2026 | Grant | ABOS Acumen Pharmaceuticals, Inc. Common Stock | $20.00M | +6.1M +46.47% | 19,103,785 26.42% of shares | low |
| Mar 27, 2026 | Buy | WVE Wave Life Sciences Ltd. Ordinary Shares | $16.05M | +2.5M +10.62% | 26,004,414 13.20% of shares | high |
| Apr 6, 2026 | Sell | VOR Vor Biopharma Inc. Common Stock | $8.88M | -538K -10.45% | 4,607,244 7.79% of shares | medium |